secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001140361-25-006302
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma FY2024 net loss $258.7M ($2.73/sh); cash $372.3M; RP-A501 Phase 2 ongoing
--------------------------------------------------------------------------------

- Net loss $258.7M ($2.73/sh) for FY2024 vs $245.6M ($2.92/sh) in FY2023.
- Cash, equivalents and investments $372.3M at Dec 31, 2024; runway into Q3 2026.
- Raised $182.5M net via Dec 2024 offering of 15.2M shares at $12.50/sh.
- RP-A501 Phase 2 pivotal dosing ongoing; NEJM publication shows efficacy up to 5 years.
- RP-A601 low dose cohort fully enrolled; initial data expected H1 2025. BAG3-DCM IND on track H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125006302/0001140361-25-006302-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125006302/ef20044486_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-006302

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer